Linagliptin shown to reduce blood glucose in older patients

08/18/2013 | Genetic Engineering & Biotechnology News

Elderly patients with type 2 diabetes who received linagliptin, a dipeptidyl peptidase-4 inhibitor, showed significant reductions in blood glucose levels compared with those treated with a placebo, according to a study in The Lancet. After 24 weeks on linagliptin, the mean change from baseline in A1C was -0.64%. The safety and tolerability profile was comparable to that of the placebo.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ